Stanford develops an experimental two-in-one shot that might give diabetics better control over blood sugar levels

Researchers have developed a way to combine insulin with a second hormone known as amylin, to create a two-in-one injection that could, if proven safe and effective in human trials, make it easier for diabetics to more effectively control their blood sugar levels.

A Stanford research team has developed a way to boost the effectiveness of the insulin injections people with diabetes routinely take to control their blood sugar.

By combining insulin with a second hormone, researchers have created a two-in-one injection that could, if proven safe and effective, one day enable people with diabetes to better control their blood sugar levels. (Image credit: iStock photo)

Led by materials scientist Eric Appel, the advance might enable patients with diabetes to take a double-acting shot that contains insulin in combination with a drug based on a second hormone, known as amylin. Amylin plays a synergistic role with insulin to control blood sugar levels after eating in a way that is more effective than insulin alone and mimics what occurs naturally with a meal.

While the amylin-based drug is already commercially available, it is estimated that less than 1 percent of patients with diabetes taking insulin therapy also take this complementary treatment because the two hormones – which work together seamlessly in the body – are too unstable to coexist in the same syringe.

“Taking that second injection with the insulin shot is a real barrier for most patients. Our formulation would allow them to be given together in a single injection or in an insulin pump,” said Appel, senior author of a research paper published May 11 in Nature Biomedical Engineering.

Protective coating

The new technique involves a protective coating that wraps around insulin and amylin molecules and, for the first time, allows them to coexist in a single shot.

“This coating dissolves in the bloodstream, enabling these two important hormones to work together in a way that mimics how they function in healthy individuals,” Appel said.

So far, the researchers have tested the wrapper’s stability in the laboratory, and done preliminary experiments to see how their two-in-one injection works on the most advanced preclinical model – diabetic pigs. But, because both drugs are already on the market and the dual-drug formulation was tested in advanced models, Appel said the team need only demonstrate that their technique is nontoxic in humans to start trials in people, bringing this technology closer to market than most early-stage drugs.

Appel and his collaborators hope this approach could, one day, dramatically increase the use of amylin and lead to improved glucose management for the estimated 450 million people worldwide with either juvenile (type 1) diabetes or adult-onset (type 2) diabetes.

Although few patients with diabetes currently take the amylin-based drug after their insulin injection, those who do experience profound benefits, Appel said. Past clinical data shows that patients taking both lose weight and have better control over their blood sugar. Enhanced diabetes management can reduce the risk of serious health complications, such as renal failure, blindness, heart disease and amputations, all of which loom over anyone with diabetes.

Mimicking the body

If the wrapper approach makes it possible to combine insulin and amylin in one dose, this would offer patients with diabetes a convenient way to mimic their natural secretion in the human body. In non-diabetics, amylin is secreted from the same cells in the pancreas that produce insulin. Insulin improves the uptake of sugar by cells, removing it from the bloodstream. For its part, amylin does three things to control blood sugar. First, it stops another hormone, glucagon, from telling the body to release additional sugar that has been stored in the liver. Second, it produces a sense of “fullness” at mealtimes that reduces food intake. Third, it actually slows the uptake of food by the body, reducing the typical spike in blood sugar after a meal. All three are a boon to diabetes care.

To make it possible to pair insulin and amylin in one syringe, the researchers developed a molecular wrapper made of polyethylene glycol, or PEG, a common nontoxic chemical used in everything from cosmetics to laxatives. The Stanford team used a new type of PEG that has a sort of molecular Velcro on the end, called cucurbituril-PEG or CB-PEG. The Velcro-like abilities of CB-PEG enable it to reversibly bind to both insulin and amylin separately, shielding the unstable portions of each molecule from breakdown. Once injected into the body, however, the drugs unbind from the CB-PEG and are free to act unhindered.

“CB-PEG is an entirely new chemical entity,” Appel said.

In lab tests of stability, the researchers heated wrapped and unwrapped insulin to normal body temperature and shook it, a process known as stressed aging. They found that unprotected insulin was stable for just 10 hours in the test tube, but the “PEGylated” insulin was still fully active 100 hours later. Without the wrap, the dual-drug combo fails in just 3 hours. More impressive, however, is that the co-formulation of PEGylated insulin and amylin remained stable for at least 100 hours, which could be a long enough shelf life to mean that the combination could be delivered by insulin pumps.

In animal studies, the researchers saw significant overlap of the activity of the dual-drug formulation, an important finding that indicates the approach is closely mimicking what happens in a healthy body – including a near-total suppression of glucagon, the hormone that tells the liver to release stored sugar, even though the person has just consumed a meal.

“We’re excited about the results to say the least,” Appel said. Appel has already filed for a patent on the technology.

Appel is also a member of Stanford Bio-X, the Cardiovascular Institute, the Stanford Maternal and Child Research Institute and a faculty fellow at Stanford ChEM-H. Stanford co-authors include professor of pediatrics David M. Maahs; professor of pediatrics Bruce A. Buckingham; professor of pathology Megan Troxell; postdoctoral research fellows Anton A. A. Smith and Santiago Correa; doctoral candidates Caitlin L. Maikawa, Gillie A. Roth, Emily C. Gale, Lyndsay M. Stapleton, Joseph L. Mann, Anthony C. Yu, Abigail K. Grosskopf, Celine S. Liong, Catherine M. Meis and Doreen Chan; and clinical veterinarian Sam W. Baker. Other co-authors are from Notre Dame University.

The research was funded by the National Institutes of Health, the Stanford Diabetes Research Center, the Stanford Maternal and Child Health Research Institute, Stanford Bio-X, the PhRMA Foundation, the Novo Nordisk Foundation, the Danish Council of Independent Research and the Stanford Animal Diagnostic Lab and Veterinary Service Center.

To read all stories about Stanford science, subscribe to the biweekly Stanford Science Digest.

Media Contacts

Tom Abate, Stanford Engineering: [email protected], (650) 736-2245